- Conditions
- Hepatic Encephalopathy
- Interventions
- Rifaximin SSD, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 90
- States / cities
- Homewood, Alabama • Chandler, Arizona • Sun City, Arizona + 70 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2257–2280
of 12,560
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson Disease
- Interventions
- Placebo, UCB0022
- Other · Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Chronic Kidney Disease Stage 3
- Interventions
- AION-301, Placebo
- Biological · Drug
- Lead sponsor
- AION Healthspan, Inc.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Miami, Florida
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 20,419 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 105
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more
- Conditions
- Glomerulonephritis, Membranous, antiPLA2R Positive
- Interventions
- MOR202
- Drug
- Lead sponsor
- HI-Bio, A Biogen Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Azusa, California • San Francisco, California • Torrance, California + 8 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
- Interventions
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
- Conditions
- Major Depressive Disorder, Major Depression, Unipolar Depression
- Interventions
- fluoxetine or desipramine
- Drug
- Lead sponsor
- National Institute of General Medical Sciences (NIGMS)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Renal Insufficiency
- Interventions
- Gefapixant
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Hialeah, Florida • Orlando, Florida
- Conditions
- Alzheimer Disease
- Interventions
- AC-OLE-01-VA
- Drug
- Lead sponsor
- Cerecin
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- COPD
- Interventions
- Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 50
- States / cities
- Anniston, Alabama • Fullerton, California • Los Angeles, California + 44 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2409021, Sitagliptin, Placebo, Metformin, Sulfonylurea
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 26
- States / cities
- Concord, California • Fresno, California • Los Angeles, California + 19 more
- Conditions
- Long COVID
- Interventions
- Amygdala insula retraining
- Behavioral
- Lead sponsor
- Miami VA Healthcare System
- Federal
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida • Miami, Florida
- Conditions
- Parkinson's Disease, Dyskinesia
- Interventions
- Sarizotan HCl
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 17
- States / cities
- Fountain Valley, California • Sunnyvale, California • Miami, Florida + 14 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebo (Semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 54
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Beverly Hills, California + 47 more
- Conditions
- Bipolar 1 Disorder
- Interventions
- RAP-219, Placebo
- Drug · Other
- Lead sponsor
- Rapport Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Chino, California + 17 more
- Conditions
- Influenza
- Interventions
- VIS410 low dose, VIS410 high dose, Placebo
- Drug
- Lead sponsor
- Visterra, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 11
- States / cities
- Huntsville, Alabama • Coral Gables, Florida • Homestead, Florida + 7 more
- Conditions
- Gout
- Interventions
- ABP-671, Allopurinol
- Drug
- Lead sponsor
- Atom Therapeutics Co., Ltd
- Industry
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 33
- States / cities
- Tempe, Arizona • Tucson, Arizona • Anaheim, California + 24 more
- Conditions
- Type 2 Diabetes, Obesity & Overweight
- Interventions
- Nex Playground Activity Program
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Type 2 Diabetes
- Interventions
- Colesevelam hydrochloride
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Tuscumbia, Alabama • Jonesboro, Arkansas + 59 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Placebo, RG7774
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more
- Conditions
- Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Interventions
- Tovinontrine (CRD-750), Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 19 more
- Conditions
- Thymoma and Thymic Carcinoma
- Interventions
- octreotide acetate, prednisone
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 24
- States / cities
- Palo Alto, California • Stanford, California • Denver, Colorado + 18 more
- Conditions
- Renal Impairment
- Interventions
- Fruquintinib
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Lavior Diabetic Wound Gel, Smith & Nephew Solosite Gel Hydrogel Wound Dressing
- Drug
- Lead sponsor
- Lavior Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida